Showing results (221-230 of 421) with videos related to
Sort By:
Pageof 43
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|February 10, 2010
Human papillomavirus types 16, 18, and 31 serostatus and prostate cancer risk in the Prostate Cancer Prevention TrialSiobhan Sutcliffe, Raphael P Viscidi, Cathee Till, et al.Journal of the National Cancer Institute|August 28, 2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention TrialJoseph M Unger, Cathee Till, Ian M Thompson, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 20, 2013
Burden among partner caregivers of patients diagnosed with localized prostate cancer within 1 year after diagnosis: an economic perspectiveChunyu Li, Steven B Zeliadt, Ingrid J Hall, et al.Cancer Prevention Research (Philadelphia, Pa.)|February 28, 2020
Vitamin D Pathway and Other Related Polymorphisms and Risk of Prostate Cancer: Results from the Prostate Cancer Prevention TrialKathleen Torkko, Cathee Till, Catherine M Tangen, et al.Psychiatric Genetics|July 11, 2006
Linkage disequilibrium analyses in the Costa Rican population suggests discrete gene loci for schizophrenia at 8p23.1 and 8q13.3Consuelo Walss-Bass, Ana Patricia Montero, Regina Armas, et al.Therapeutic Advances in Medical Oncology|November 19, 2010
COOPERATIVE GROUP TRIALS - SOUTHWEST ONCOLOGY GROUP (SWOG) INNOVATIONS IN ADVANCED PROSTATE CANCERTanya B Dorff, Cathy M Tangen, E David Crawford, et al.The American Journal of Managed Care|May 12, 2010
Preliminary treatment considerations among men with newly diagnosed prostate cancerSteven B Zeliadt, Carol M Moinpour, David K Blough, et al.JAMA Oncology|November 7, 2024
Long-Term Adverse Effects and Complications After Prostate Cancer TreatmentJoseph M Unger, Cathee Till, Catherine M Tangen, et al.Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|October 13, 2006
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trialZhihong Gong, Marian L Neuhouser, Phyllis J Goodman, et al.Oncotarget|June 19, 2023
Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancerDevalingam Mahalingam, Salih Hanni, Anthony V Serritella, et al.Pageof 43